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Keywords 
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  Non-refreshed sleep is a common symptom in fibromyalgia.  Polysomnography showed reduced slow-wave sleep and alpha waves during non-rapid eye movement sleep 
in patients with fibromyalgia.  Epidemiological studies suggested poor quality sleep in normal population is a risk factor for the 
development of chronic widespread pain.  In healthy individuals, disrupting sleep impaired pain processing with reduction in descending pain 
modulation and led to fibromyalgia-like symptoms.  Improving sleep quality is associated with reduction in pain.  Among currently available pharmacological treatments, evidence suggested amitriptyline and pregabalin 
improve sleep in fibromyalgia 
 
Fibromyalgia is characterized by chronic widespread pain, fatigue and nonrestorative sleep. Polysomnography 
showed reduced short-wave sleep and abnormal alpha rhythms during Non-rapid eye movement sleep in patients 
with fibromyalgia. However, sleep dysfunction might be pathogenic in fibromyalgia since myalgia and fatigue could 
be induced in healthy individuals by disrupting sleep. Poor sleep quality was a major risk factor for the subsequent 
development of chronic widespread pain in healthy pain-free individuals. Sleep disruption leads to impairment of 
the descending pain inhibition pathways. Aside from good sleep, hygiene, exercise can promote sleep. Among 
currently available pharmacological treatments, evidence suggests amitriptyline and pregabalin can improve sleep in 
fibromyalgia 
 
Background 
Fibromyalgia is a common cause of chronic musculoskeletal pain [1]. The condition is not new but the diagnosis has 
been made more frequent since the publication of the American College of Rheumatology (ACR) criteria in 1990 
[2]. The 1990 ACR ‘classification’ criteria for fibromyalgia required the presence of bilateral pain above and below 
the waist for at least 3 months as well as the presence of at least 11 out of 18 tender points. Although the main 
objective of the ACR 1990 criteria was to facilitate research by defining a homogenous patient population, they have 
been used routinely in clinical practice. Based on the ACR 1990 classification criteria, the prevalence of fibromyalgia 
in the general population ranges from 0.5 to 4%. Initially, the diagnosis of fibromyalgia had been controversial, 
however, the publication of several national guidelines by the American Pain Society [3], European League Against 
Rheumatism [4], German Pain Society [5] and Canadian Pain Society/Canadian Rheumatology Association [6] have 
established the clinical standards for diagnosis and management 
 
Tender points & tenderness in fibromyalgia 
The inclusion of tender point count as a criterion for ACR 1990 classification criteria led to its  Although widely 
used, some studies have questioned their diagnostic validity. One of the key criticism is that fibromyalgia is a 
polysymptomatic condition. Aside from pain, other symptoms including fatigue, nonrestorative sleep and cognitive 
impairment are common. Fatigue and nonrestorative sleep affects over 70% of patients with fibromyalgia who often 
complain of waking in the morning not ‘refreshed’ and feeling tired. Indeed, they may sleep through the night but 
still feel fatigue in the morning [7]. Daytime somnolence is common. In 2011, preliminary diagnostic criteria for 
fibromyalgia was published [8,9] which removed the requirement for the presence of tender points. Instead, patient 
must meet criteria for a sufficiently high symptom severity scale (SSS) score. SSS score is composed of fatigue, non-
refreshed upon waking and cognitive symptoms plus the extent of somatic symptoms. The 2011 preliminary criteria 
recognized the importance of these symptoms in the manifestations of fibromyalgia.  Non-refreshed upon waking is 
a key feature of poor sleep quality. 
 
 
Current treatment of fibromyalgia  
Treatment for fibromyalgia is a major unmet medical need. Current treatments alleviate symptoms but do not lead 
to remission. In most patients, a multidisciplinary approach, combining nonpharmacological and pharmacological 
treatments, is needed [10]. Medications recommended for the treatment of fibromyalgia include simple analgesia, 
tramadol and tricyclic antidepressants [11] such as amitriptyline as well as three medications that have been 
approved by the US FDA for the treatment of fibromyalgia in North America: pregabalin and two 
serotoninnorepinephrine reuptake inhibitors (SNRIs:  milnacipran and duloxetine [12]. Gabapentin, a structural 
analog of pregabalin, is approved for the treatment of neuropathic pain and also commonly used in treatment of 
fibromyalgia. 
 
Abnormal pain processing in the pathophysiology in fibromyalgia 
Although there have been controversies about the diagnostic utility of tender point count in fibromyalgia, increased 
‘tenderness’ is a consistent observation. Patients experience pain to light pressure/touch, which is indicative of 
allodynia, a feature of abnormal pain processing [13]. In fibromyalgia abnormal pain processing attributed to central 
sensitization has been demonstrated by many studies [14–19]. Neuroimaging using functional MRI (fMRI), in 
patients with fibromyalgia and healthy individuals,  found similar neuronal activation corresponding to patient 
reported pain severity. However, in patients with fibromyalgia, lower pressure was needed to elicit the same neural 
activity [20]. Abnormalities in both the ascending and descending pain pathways have been implicated in the 
pathogenesis of central sensitization in fibromyalgia. Elevated levels of glutamate, substance P and NGF were found 
in cerebral spinal fluid [21–24] and decreased cortical gray matter density had been detected in higher brain regions 
[25–32]. These studies suggested abnormalities in the ascending pain pathway. Other studies have found 
abnormalities implicating the descending inhibitory pathways with reduced levels of serotonin and norepinephrine in 
the cerebral spinal fluid [33], which probably accounts for the efficacy of antidepressants, especially SNRIs. Reduced 
activity in the rostral anterior cingulate cortex, a region of the brain associated with the descending pain inhibitory 
pathways has been demonstrated by fMRI scan in patients with fibromyalgia compared with healthy controls [34]. 
Positron emission tomography also found reduced μ-opioid receptor binding potential in the rostral anterior 
cingulate cortex [35], provided objective evidence that pain processing is impaired in fibromyalgia given the vital role 
of endogenous opioids pathway in pain modulation. In addition, in fibromyalgia, abnormalities in the inhibitory 
conditioned pain modulation (ICPM) pathways have also been shown [36–39]. Since pain facilitation from the 
ascending pathways are strongly linked to the descending pain inhibitory pathways, their relative contribution in the 
pathophysiology of fibromyalgia remains unclear 
 
The role of sleep in pathogenesis of fibromyalgia 
Disturbed sleep is common in patients with fibromyalgia [40]. Wakening feeling nonrefreshed is included in the SSS 
score of the 2011 preliminary fibromyalgia diagnostic criteria. Patients and physicians have presumed disturbed sleep 
is a consequence of pain until Moldofsky et al. found that in healthy individuals disrupting sleep by auditory stimuli 
during short-wave sleep (SWS) induced myalgia, fatigue and reduced pressure pain threshold [41]. Subsequently, 
many studies have implicated sleep in the pathogenesis of fibromyalgia. First, poor sleep quality is associated with 
worsening of pain and fatigue in fibromyalgia [42]. Second, sleep disturbance aggravates the effect of pain on fatigue 
and mood. Path analysis found that a night of poor sleep led to worsen pain and mood with reduced physical 
functioning [43]. Third, poor sleep quality predicts development of fibromyalgia in healthy individuals. In a study of 
12,350 painfree women from Norway, 327 developed fibromyalgia.  Poor sleep quality was associated with increased 
risk of developing fibromyalgia in a dose-dependent manner [44]. A recent UK study in 4326 healthy subjects also 
found nonrestorative sleep was strongest predictor of subsequent development of widespread pain after adjusting 
for psychosocial factors [45]. 
 
Sleep dysfunction in fibromyalgia 
Sleep is divided into two main stages: rapid and nonrapid eye movements. Nonrapid eye movement is further 
categorized into light, intermediate and SWS. The latter is essential to feeling refeshed upon awakening. 
Polysomnography studies in fibromyalgia found that SWS was reduced and interrupted [46,47]. In healthy 
individuals, the duration of SWS is directly dependent on the period of prior wakefulness. Prolonged arousal will 
extend duration of SWS. In patients with fibromyalgia, prominent alpha waves have been found during nonrapid eye 
movement, especially SWS. Since alpha waves are associated with wakefulness, they have been hypothesized to 
represent an arousal or awakening state in fibromyalgia [48]. 
 
Disturbed sleep impairs pain processing 
The potential role of sleep disturbance in the pathogenesis of fibromyalgia has been strengthened by recent studies 
showing that disruption of sleep could impair pain processing. In healthy individuals, disrupting sleep reduce activity 
in descending inhibitory pain pathways [49–52].  Restoration of sleep improves pain with increase in pressure pain 
threshold to normality. Chronic pain is more common in patients with primary sleep disorders such as narcolepsy 
and cataplexy than the normal population [53]. In these patients, sleep and depression were major determinants on 
severity of pain. 
 
 
Effect of current treatment for fibromyalgia on sleep 
A recent systematic review and meta-analysis examined the effect of current nonpharmacological and 
pharmacological treatment on different core symptoms of fibromyalgia [54]. Studies on nonpharmacological 
treatments often combined several treatments. There is low-quality evidence  to suggest exercise, cognitive–
behavioral therapy and balneotherapy might improve sleep. For pharmacological interventions, low-dose 
amitriptyline had a moderate effect on improving pain, sleep and fatigue but no effect on mood. The effect of other 
anti-depressants, which include SNRI (milnacipran, duloxetine) and selective serotonin reuptake inhibitors (SSRIs; 
citalopram and fluoxetine) were small with effect sizes of less than 0.3. For SNRI, improvement in sleep was not 
statistically significant. Pregabalin had a small effect on pain (effect size: 0.31) but moderate effect on sleep (effect 
size: 0.57). However, caution is needed to interpret these data since the patient populations enrolled in these trials 
were different. Many patients recruited to trials of SNRI, SSRI and pregabalin had previously failed amitriptyline so 
direct comparison between SNRI, SSRI and pregabalin versus  
amitriptyline should be avoided. 
 
Effect of SNRI on sleep 
A secondary analysis of duloxetine on fatigue and sleep in patients with fibromyalgia found that duloxetine versus 
placebo statistically significantly reduced fatigue, pain, anxiety, depressed mood and stiffness. Improvement in the 
rating of ‘being bothered by sleep difficulties’ was significant only at week 4 and 8 [55]. A study on milnacipran using 
polysomnography found that milnacipran did not improve ‘wake after sleep onset’ or ‘number of awakenings after 
sleep onset’ but reduced sleep efficiency [56]. Together these data suggested that SNRI improved sleep by reducing 
pain rather than having a direct effect on sleep.  
 
Effect of pregabalin on sleep 
Pregabalin was developed initially as an anticonvulsant and subsequently approved for the treatment of anxiety, 
neuropathic pain and fibromyalgia. A pool analysis of Phase II and III randomized control trials of pregabalin in 
fibromyalgia found that pregabalin reduced pain and improved sleep quality [57]. A subsequent randomized 
placebo-controlled trial of pregabalin in 197 patients with fibromyalgia with comorbid depressant and taking 
concurrent anti-depressants (SNRI or SSRI) [58] also found that pregabalin reduced pain, anxiety and depression as 
well as improved sleep quality when compared with placebo-treated patients. However, these results were based on 
patient’s report of sleep quality. In a recent randomized, placebocontrolled, crossover trial, 119 patients with 
fibromyalgia with disturbed sleep defined as wake after sleep onset ≥45 min and total sleep time of 3–6.5 h received 
either 150–450 mg/day of pregabalin or placebo [59]. Polysomnography was performed for two consecutive nights 
at screening and post-treatment. Pregabalin decreased number of wake/sleep bouts (-3.61 min; p = 0.0039) and 
increased sleep bout duration (+3.67, min; p < 0.0001). Slow-wave sleep correlated positively with sleep bout 
duration and negatively with wake/sleep bout number. The result of this study suggested pregabalin improved sleep 
quality with an increase in ‘deep sleep’. The results from these studies were supported by a systematic review and 
indirect comparison of pharmacological treatments for fibromyalgia, which found pregabalin, milnacipran and 
duloxetine reduced pain and improved physical function [60]. However, pregabalin produced statistically 
significantly greater improvements in sleep compared with milnacipran. Dosing of pregabalin and SNRI was based 
on pharmacokinetics and adopted from their use in other indications such as anxiety and depression. For improving 
sleep, it may be more effective if they are taken as a single dose in the evening. This should be examined in future 
clinical trial.  
 
 
Trials of sleep modifiers in fibromyalgia 
Good sleep hygiene practices should be recommended to patients with fibromyalgia with nonrestorative sleep. 
These include avoiding stimulants (such as caffeine), large meals and alcohol too close to bedtime. Although alcohol 
can speed the onset of sleep, it disrupts sleep in the second half of the night. Exercise can promote sleep. As yet, no 
current recommended medication for the treatment of fibromyalgia is known to reverse all polysomnographic 
abnormalities associated with fibromyalgia [61]. 
 
Benzodiazepines 
Benzodiazepines such as zolpidem and zopiclone are commonly prescribed medications for insomnia. However, 
they have no or limited effect on sleep architecture and do not affect SWS [62,63].  Indeed, most patients with 
fibromyalgia do not complain of insomnia, but disturbed sleep such as frequent awakening at night [1]. Randomized 
control trials of zolpidem and zopiclone found limited efficacy in fibromyalgia [64,65].  Polysomnography study of 
ziploclone confirmed it has no effect on sleep architecture.  
 
Sodium oxybate 
Sodium oxybate is a sleep modifier licensed for the treatment of excessive daytime sleepiness associated with 
narcolepsy. It is metabolized to gamma-hydroxybutyrate, and acts as an agonist of the gamma-
aminohydroxybutyrate and gamma-hydroxybutyrate receptors. It improves sleep architecture [66] but has no known 
effect on pain. Hitherto, it is the only treatment, which has been trialed in fibromyalgia that targets specifically sleep 
dysfunction. Several randomized placebo-controlled trials of sodium oxybate have been conducted in fibromyalgia 
[67–70]. Sodium oxybate reduced sleep disturbance and fatigue with a medium effect size. It also reduced pain with 
effect size at least comparable to current recommended treatment such as tricyclic antidepressant.  A path analysis 
confirmed that sodium oxybate had no direct effect on pain.  Reduction in pain was almost entirely mediated by 
improvements in sleep [71]. However, the prescription of sodium oxybate is highly controlled and regulated. It is 
fast-acting and induces deep sleep. Fallen in the wrong hands, it has been used as a date rape drug. Hence, it is not 
recommended for the treatment of fibromyalgia. However, these studies are mechanistically important. If sleep 
dysfunction is secondary to pain, then sodium oxybate should improve sleep but not pain. The therapeutic effect of 
sodium oxybate on pain suggests sleep dysfunction has an important role in abnormal pain processing in 
fibromyalgia.  
 
Melatonin 
Melatonin is a hormone released from the pineal gland during darkness. It regulates sleep–wake cycle.  Melatonin is 
available as an over-the-counter medicine in North America which has been used commonly for reducing jet lag and 
shift workers to adapt to sleeping during the day. In many countries, melatonin is a prescription-only medicine used 
for treating insomnia or sleep dysfunction associated with a variety of disorders. A systematic review and meta-
analysis of melatonin in 1683 patients with primary sleep disorders from 19 studies found that melatonin 
demonstrated significant efficacy in reducing sleep latency and increasing total sleep time [72]. Overall sleep quality 
was significantly improved in subjects taking melatonin compared with placebo although the absolute benefit was 
smaller than other pharmacological treatments for insomnia. However, the correct dosage of melatonin needed to 
treat sleep dysfunction is unclear [73]. Some research suggested that lower doses (0.3–1.0 mg) may be more 
efficacious than the commercially available doses which are three- to ten-times normal level in the body. 
Furthermore, higher doses of melatonin may have side effects, which include headache, short-term feelings of 
depression, daytime sleepiness, dizziness, vivid dreams and nightmares. Shorter term used of melatonin is safe but 
side effect after regular long-term usage is not known.  
 
In a control trial of melatonin in 63 patients with fibromyalgia, patients were randomized to receive 25 mg 
amitriptyline, 10 mg melatonin or a combination of both for 6 weeks [74]. Melatonin alone or in combination with 
amitriptyline reduced significantly pain and increased the inhibitory pain-modulating system as assessed by 
conditional pain modulation by hot heat task and pressure pain threshold. Combining melatonin with amitriptyline 
led to greater improvement in physical functioning. Sleep quality as assessed by the Pittsburg Sleep Questionnaire 
showed similar improvement with melatonin alone, amitriptyline alone or a combination of both.   
 
A number of melatonin receptor agonists, ramelteon and tasimelteon have been developed and approved for the 
treatment of sleep disorders. Their therapeutic potential in fibromyalgia should be explored in randomized placebo-
controlled trial. 
 
Cyclobenzapine 
Cyclobenzapine was found to be effective in reducing pain and improving sleep in a 12-week double-blind 
randomized control trials in patients with fibrositis [75]. Three double-blind, randomized placebo-controlled trials 
reported that cyclobenzaprine was more effective than placebo in alleviating symptoms of fibromyalgia and 
improving sleep [76–78]. A meta-analysis of fivestudies suggested that cyclobenzaprine had moderate beneficial 
effect on individual symptoms, particularly sleep [79]. A recent small double- blind, placebo-controlled, dose-
escalating study evaluated the short-term effects of very low-dose cyclobenzaprine in patients with fibromyalgia after 
8 weeks on sleep using polysomnography [80]. Compared with placebo-treated patients, cyclobenzaprine improved 
pain, fatigue, tenderness and depression. Polysomnography showed that cyclobenzaprine increased number of 
nights of restorative sleep. Large Phase III trial of cyclobenazpine will be needed to establish its therapeutic role in 
fibromyalgia.  
 
Nabilone 
Several cannabinoids have been developed for  the treatment of chronic pain. Nabilone is a synthetic cannabinoid, 
which has been studied in fibromyalgia. A double-blind randomized crossover trial compared the short-term effect 
of nabilone on sleep with low-dose amitriptyline in 31 patients with fibromyalgia and chronic insomnia for 2 weeks 
[81].  
 
Nabilone was superior to amitriptyline as assessed by Insomnia Severity Index and restfulness but not on 
wakefulness. However, no effects on pain, mood or quality of life were observed in this short study. 
 
Conclusion 
Fibromyalgia is a common cause of chronic widespread pain in which nonrefreshed sleep is a common symptom. 
Polysomnography found reduced slow-wave sleep and intrusion of alpha waves suggestive of a lack of ‘deep sleep’. 
Although severe pain may lead to sleep dysfunction, both epidemiological and experimental studies have suggested 
sleep dysfunction may lead to the development of fibromyalgia.  In healthy individuals, sleep disruption impairs pain 
processing with reduction in descending pain modulation. among currently available pharmacological treatments, 
there is evidence to suggest amitriptyline and pregabalin can improve sleep quality. Trials of sodium oxybate showed 
that improving sleep could reduce pain and fatigue and therefore key symptom domains in fibromyalgia. This is an 
important therapeutic strategy for developing new treatments for fibromyalgia. However, new treatment must 
improve sleep architecture. Polysomnographic evidence demonstrating effect of treatment on sleep architecture is 
important during clinical development of new treatments. Currently, there are few medications that can improve 
sleep architecture. Melantonin receptor agonists and cyclobenzaprine showed promise in preliminary studies but 
more detailed studies will be needed to establish their effect of sleep and pain in fibromyalgia. 
 
Future perspective 
Traditionally, sleep disturbance is considered to be a consequence of pain. In fibromyalgia, there is sufficient 
evidence to suggest improving sleep quality may be an effective treatment strategy.  While treatments such as 
benzodiazepines are available for insomnia, they do not improve or prolong SWS. Trials of cyclobenzaprine will 
inform further improving sleep quality is effective treatment strategy in fibromyalgia. If successful, it may drive 
further pharmaceutical development. 
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